本報告已在2012年02月22日停止出版。
急性淋巴性白血病治療市場由於淋巴性白血病的罹患人口增加，預計從2015年到2020年的年平均成長率將為5.21%。就各地區來看北美市場的市場佔有率最高，2010年佔整體銷售量的58%。再就治療法來看，Hyper-CVAD療法是最主流的治療法，佔同年的整體銷售量39.40%。急性淋巴性白血病由於尚有許多初期診斷上的未滿足需求，而為治療法相當受限的一個領域。
本報告提供北美，歐洲，日本的急性淋巴性白血病治療市場現況與展望調查分析，目前化療/化療藥的收益規模轉變與預測(∼2020年)，各國家、各療法/藥物的詳細內容，開發平台藥的開發趨勢，競爭環境，並彙整主要企業簡介等，為您概述為以下內容。
第1章 簡介
第2章 摘要整理
第3章 市場概要
第4章 急性淋巴性白血病:市場動態
第5章 白血病治療藥物市場
- 市場概要
- HYPER-CVAD療法
- CALGB 8811療法
- 連接試劑療法
- 核苷酸代謝抑制劑(CLOLAR + ARRANON)
- ONCASPAR(onkyasupa)
第6章 白血病治療藥物的平台(階段III)
第7章 地區分析
- 美國
- 加拿大
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 日本
第8章 競爭環境
第9章 企業簡介
- ARIAD PHARMACEUTICALS INC
- ERYTECH PHARMA
- GENZYME CORPORATION
- TALON THERAPEUTICS INC
圖表
Abstract
Report Description
The incidence of acute lymphocytic leukemia is high in children from 0 to 14
years than the people aged above 14. It is the most common childhood acute
lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur
in adults. Acute lymphocytic leukemia distribution depends on age. For
instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The
acute lymphocytic leukemia market is segmented into two types; namely
childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia.
The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the
market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
This report studies the market from 2010 to 2020 covering eight major regimens
and single drugs (off-patent and pipeline) for acute lymphocytic leukemia
treatment. Growing acute lymphocytic leukemia population is an impetus for the
growth of the market. This market is expected to grow at a CAGR of 5.21% from
2015 to 2020. North America was the major contributor to this market;
accounting for 58% of the total sales of acute lymphocytic leukemia drugs in
2010; whereas Hyper-CVAD was the major regimen accounting for 39.40% of the
total sales of acute lymphocytic leukemia drugs in 2010. Acute lymphocytic
leukemia is still an area with high unmet need for early diagnosis and limited
treatment options in this area.
The report studies six existing regimens and single drugs for leukemia market.
Currently, there are about two major drugs in pipeline for acute lymphocytic
leukemia expecting a market launch by 2012. Talon Therapeutics Inc submitted
new drug application to FDA for Marqibo in July 2011, leading to its market
launch by 2012.
Graspa will be launched in the market in 2012 by ERYtech Pharma (France) on
receiving Orphan Drug Designation (ODD) grant from the FDA in 2010. The drug
is expected to be priced at $420 for patients who take them annually.
Players are implementing various growth strategies in the market to gain a
competitive edge. New product launches, product pipelines, agreements and
collaborations, clinical trials, and acquisitions were the major strategies
adopted by the players from January 2008 to September 2011.
Pipeline drugs form a major growth strategy in the acute lymphocytic leukemia
therapeutics market in G8 countries; accounting for 40% share in this market
between January 2008 and September 2011, followed by agreements and
collaborations with a 27% share, and approvals with a 20% share.
GlaxoSmithKline Pharmaceuticals Limited and Genzyme Corporation rule the
present market for acute lymphocytic leukemia drugs; whereas ERYtech Pharma &
Talon Therapeutic Inc are expected to capture major share of the market by
2020.
Scope of the report
This acute lymphocytic leukemia therapeutics market research report evaluates
the leukemia therapeutics market with respect to the current and pipeline
drugs and regimens. The report analyzes geography; forecasting revenue, and
trends in each of the following submarkets:
- Chemotherapy regimens
- Hyper-CVAD
- CALGB 8811 regimen
- Linker regimen
- Chemotherapy drugs
- Clolar
- Nelarabine
- Oncaspar
- Pipeline drugs
The geographies covered under the report are:
- North America
- Europe
- UK
- Germany
- Italy
- France
- Spain
- Japan
Each section provides market data, market drivers, trends and opportunities,
key players, and competitive outlook. The report makes provisions for market
tables to cover the sub-segments and micro-markets. Additionally, it makes
ways for company profiles that cover all the sub-segments. The report has been
made by keeping past trends, current happenings and future forecasts in
consideration.
Summary
In acute lymphocytic leukemia, the body rapidly produces a large number of
immature white blood cells, called lymphocytes. These immature white blood
cells replace normal cells in the bone marrow. This type of cancer can be
sub-categorized into childhood acute lymphocytic leukemia and adult acute
lymphocytic leukemia. The childhood acute lymphocytic leukemia can further
divided into standard risk group, high risk group, and recurrent childhood
ALL. The adult acute lymphocytic leukemia can be further divided into the
untreated ALL, adult ALL in remission, and recurrent adult ALL.
It is the most common childhood acute leukemia. However, this leukemia may
also occur in adults. Acute lymphocytic leukemia accounts for about 20% to 25%
of all the childhood cancers. Acute lymphocytic leukemia prevalence is high
among one to four year old children and it is almost eight times more than the
young adults aged between 20 and 24.
Acute lymphocytic leukemia is expected to be more prominent in the developed
and in higher socioeconomic groups. Radiation exposure is the primary cause of
acute lymphocytic leukemia. Global incidence of acute lymphocytic leukemia was
32,558 in 2008 with the developing countries. Total 42,301 new cases were
recorded in 2010 with 68,390 and 96,920 as the predicted new cases for 2015
and 2020.
Leukemia is rarely associated with pregnancy, affecting only about 1 in 10,000
pregnant women. How it is handled depends primarily on the type of leukemia.
Nearly all leukemias appearing in pregnant women are acute leukemias. Acute
leukemias normally require prompt, aggressive treatment, despite significant
risks of pregnancy loss and birth defects, especially if chemotherapy is given
during the developmentally sensitive first trimester.
Table of Contents
1 INTRODUCTION
- 1.1 KEY TAKE-AWAYS
- 1.2 REPORT DESCRIPTION
- 1.3 MARKETS COVERED
- 1.4 STAKEHOLDERS
- 1.5 RESEARCH METHODOLOGY
- 1.5.1 MARKET SIZE
- 1.5.2 KEY DATA POINTS TAKEN FROM SECONDARY SOURCES
- 1.5.3 ASSUMPTIONS MADE FOR THIS REPORT
2 EXECUTIVE SUMMARY
- 2.1 OVERVIEW OF THE MARKET
3 MARKET OVERVIEW
- 3.1 DEFINING LEUKEMIA
- 3.2 DEFINING ACUTE LYMPHOCYTIC LEUKEMIA
- 3.2.1 RISK FACTORS
- 3.2.2 STAGES/PHASES OF ACUTE LYMPHOCYTIC LEUKEMIA
- 3.2.2.1 Childhood ALL
- 3.2.2.1.1 Standard (low) risk
- 3.2.2.1.2 High risk
- 3.2.2.1.3 Recurrent
- 3.2.2.2 Adult ALL
- 3.2.2.2.1 Untreated adult ALL
- 3.2.2.2.2 Adult ALL in remission
- 3.2.2.2.3 Recurrent adult ALL
- 3.2.3 DIAGNOSIS
- 3.2.3.1 Biopsy and bone marrow aspiration
- 3.2.3.2 Complete blood count (CBC) and differential
- 3.2.3.3 Philadelphia chromosome's presence
- 3.2.3.4 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF)
analysis
- 3.2.3.5 Immunophenotyping or phenotyping by flow cytometry
- 3.2.3.6 Polymerase chain reaction (PCR)
- 3.2.4 LEUKEMIA PREVALENCE
- 3.2.5 INCIDENCE & MORTALITY
- 3.3 MARKET STRUCTURE
- 3.3.1.1 Key therapies
- 3.3.1.1.1 Chemotherapy
- 3.3.1.1.2 Stem cell/bone marrow transplant
- 3.3.1.1.3 Radiation therapy
4 ACUTE LYMPHOCYTIC LEUKEMIA MARKET DYNAMICS
- 4.1 MARKET OVERVIEW
- 4.2 BURNING ISSUES
- 4.3 WINNING IMPERATIVES
- 4.3.1 STRATEGY OF MARKET EXPANSION BY UTILIZING MULTIPLE THERAPEUTIC
APPROACHES
- 4.4 MARKET DYNAMICS
- 4.4.1 MARKET DRIVERS
- 4.4.1.1 Innovative therapies to drive the market for leukemia
- 4.4.1.2 Oncology is the largest therapeutic market with high unmet
needs
- 4.4.2 MARKET RESTRAINTS
- 4.4.2.1 Low production capability for efficient drugs
- 4.4.3 MARKET OPPORTUNITIES
- 4.4.3.1 Limited players in the market
- 4.4.3.2 Leukemia's underserved patient populations offer potential for
market growth
5 LEUKEMIA PRODUCT MARKET
- 5.1 MARKET OVERVIEW
- 5.1.1 HYPER-CVAD REGIMEN
- 5.1.2 CALGB 8811 REGIMEN
- 5.1.3 LINKER REGIMEN
- 5.1.4 NUCLEOSIDE METABOLIC INHIBITORS (CLOLAR + ARRANON)
- 5.1.5 ONCASPAR
6 LEUKEMIA DRUG PIPELINE (PHASE III)
- 6.1 PIPELINE DRUGS
- 6.1.1 GRASPA
- 6.1.2 MARQIBO
7 GEOGRAPHIC ANALYSIS
- 7.1 U.S.
- 7.2 CANADA
- 7.3 U.K.
- 7.4 GERMANY
- 7.5 FRANCE
- 7.6 ITALY
- 7.7 SPAIN
- 7.8 JAPAN
8 COMPETITIVE LANDSCAPE
9 COMPANY PROFILES
- 9.1 ARIAD PHARMACEUTICALS INC
- 9.1.1 OVERVIEW
- 9.1.2 FINANCIALS
- 9.1.3 PRODUCTS & SERVICES
- 9.1.4 DEVELOPMENTS
- 9.2 ERYTECH PHARMA
- 9.2.1 OVERVIEW
- 9.2.2 FINANCIALS
- 9.2.3 PRODUCTS & SERVICES
- 9.2.4 STRATEGY
- 9.2.5 DEVELOPMENTS
- 9.3 GENZYME CORPORATION
- 9.3.1 OVERVIEW
- 9.3.2 FINANCIALS
- 9.3.3 PRODUCTS & SERVICES
- 9.3.4 STRATEGY
- 9.3.5 DEVELOPMENTS
- 9.4 TALON THERAPEUTICS INC
- 9.4.1 OVERVIEW
- 9.4.2 FINANCIALS
- 9.4.3 PRODUCTS & SERVICES
- 9.4.4 STRATEGY
- 9.4.5 DEVELOPMENTS
LIST OF TABLES
- TABLE 1 YEARLY COST OF DRUGS IN NORTH AMERICA & JAPAN, 2011 ($)
- TABLE 2 YEARLY COST OF DRUGS IN EUROPEAN COUNTRIES, 2011 ($)
- TABLE 3 DOSAGE PATTERN OF DRUGS
- TABLE 4 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY
REGIMENS/DRUGS, 2008 - 2020 ($MILLION)
- TABLE 5 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PATENT STATUS
- TABLE 6 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY TYPES, 2008 -
2020 ($MILLION)
- TABLE 7 ACUTE LYMPHOCYTIC LEUKEMIA DRUG/REGIMENS MARKET REVENUE, 2008 -
2020 ($MILLION)
- TABLE 8 ACUTE LYMPHOCYTIC LEUKEMIA REGIMEN (HYPER-CVAD) MARKET REVENUE, BY
COUNTRY, 2008 - 2020 ($MILLION)
- TABLE 9 ACUTE LYMPHOCYTIC LEUKEMIA REGIMEN (CALGB 8811) MARKET REVENUE, BY
COUNTRY, 2008 - 2020 ($MILLION)
- TABLE 10 ACUTE LYMPHOCYITC LEUKEMIA DRUGS (LINKER REGIMEN) MARKET REVENUE,
BY COUNTRY, 2008 - 2020 ($MILLION)
- TABLE 11 ACUTE LYMPHOCYTIC LEUKEMIA DRUG CLASS (NUCLEOSIDE METABOLIC
INHIBITORS) MARKET REVENUE, BY COUNTRY, 2008 - 2020 ($MILLION)
- TABLE 12 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS (ONCASPAR) MARKET REVENUE, BY
COUNTRY, 2008 - 2020 ($MILLION)
- TABLE 13 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE (GRASPA) MARKET
REVENUE, BY COUNTRY, 2015 - 2020 ($MILLION)
- TABLE 14 ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE (MARQIBO) MARKET
REVENUE, BY COUNTRY, 2015 - 2020 ($MILLION)
- TABLE 15 SEER STATISTICS FOR LEUKEMIA (ESTIMATED) IN U.S., 2011
- TABLE 16 U.S: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY
DRUGS/REGIMENS, 2008 - 2020 ($MILLION)
- TABLE 17 U.S: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE MARKET REVENUE,
BY DRUGS, 2008 - 2020 ($MILLION)
- TABLE 18 CANADA: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY
DRUGS/REGIMENS, 2008 - 2020 ($MILLION)
- TABLE 19 CANADA: LEUKEMIA DRUGS - PIPELINE MARKET REVENUE, BY DRUGS, 2015
- 2020 ($MILLION)
- TABLE 20 U.K: INCIDENCE BY GENDER & TYPE OF LEUKEMIA, 2010
- TABLE 21 U.K: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 -
2020 ($MILLION)
- TABLE 22 U.K: LEUKEMIA DRUGS - PIPELINE MARKET REVENUE, BY DRUGS, 2015 -
2020 ($MILLION)
- TABLE 23 GERMANY: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 -
2020 ($MILLION)
- TABLE 24 GERMANY: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE MARKET
REVENUE, BY DRUGS, 2015 - 2020 ($MILLION)
- TABLE 25 FRANCE: LEUKEMIA DRUGS MARKET REVENUE, BY DRUGS/REGIMENS, 2008 -
2020 ($MILLION)
- TABLE 26 FRANCE: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE MARKET
REVENUE, BY DRUGS, 2015 - 2020 ($MILLION)
- TABLE 27 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY
DRUGS/REGIMENS, 2008 - 2020 ($MILLION)
- TABLE 28 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE MARKET
REVENUE, BY DRUGS, 2015 - 2020 ($MILLION)
- TABLE 29 SPAIN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY
DRUGS/REGIMENS, 2008 - 2020 ($MILLION)
- TABLE 30 SPAIN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE MARKET
REVENUE, BY DRUGS, 2008 - 2020 ($MILLION)
- TABLE 31 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS MARKET REVENUE, BY
DRUGS/REGIMENS, 2008 - 2020 ($MILLION)
- TABLE 32 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA DRUGS - PIPELINE MARKET
REVENUE, BY DRUGS, 2008 - 2020 ($MILLION)
- TABLE 33 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES
- TABLE 34 NEW PRODUCTS LAUNCH, 2008 - 2011
- TABLE 35 EXPANSIONS/NEW FACILITY/INVESTMENTS, 2011
- TABLE 36 FDA APPROVALS, 2008 - 2011
- TABLE 37 CLINICAL TRIALS, 2008 - 2011
- TABLE 38 NDA, BLA & MARKETING APPLICATIONS, 2008 - 2011
- TABLE 39 ARIAD PHARMACEUTICALS: TOTAL REVENUE & R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 40 ARIAD PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 41 ERYTECH PHARMA: PRODUCT PIPELINE
- TABLE 42 GENZYME CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 43 GENZYME CORPORATION: PRODUCT PORTFOLIO
- TABLE 44 TALON THERAPEUTICS INC: TOTAL R&D EXPENSES, 2008 - 2010 ($MILLION)
- TABLE 45 TALON THERAPEUTICS INC: PIPELINE PRODUCT PORTFOLIO
LIST OF FIGURES
- FIGURE 1 TOTAL ACUTE LYMPHOCYTIC LEUKEMIA MARKET, 2008 - 2020 ($MILLION)
- FIGURE 2 ACUTE LEUKEMIA MARKET REVENUE, BY REGIMENS/DRUGS, 2008 - 2020
($MILLION)
- FIGURE 3 TYPES OF LEUKEMIA
- FIGURE 4 TOTAL LEUKEMIA POPULATION, BY COUNTRY, 2008-2020
- FIGURE 5 ACUTE LYMPHOCYTIC LEUKEMIA DEVELOPMENT & PROGRESSION RATE, BY AGE
- FIGURE 6 STAGES AND PHASES OF ACUTE LYMPHOCYTIC LEUKEMIA
- FIGURE 7 ACUTE LYMPHOCYTIC LEUKEMIA POPULATION, BY COUNTRY, 2008 - 2020
- FIGURE 8 ACUTE LYMPHOCYTIC LEUKEMIA: MARKET SEGMENTATION, BY REGIMENS/DRUGS
- FIGURE 9 ACUTE LYMPHOCYTIC LEUKEMIA: EXISTING DRUGS MARKET SHARE, 2010 VS
2020
- FIGURE 10 ACUTE LYMPHOCYTIC LEUKEMIA: PIPELINE DRUGS MARKET SHARE, 2015 VS
2020
- FIGURE 11 ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET SHARE,
BY TYPES, 2010 VS 2020
- FIGURE 12 ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET SHARE,
BY TYPES, 2015 VS 2020
- FIGURE 13 U.S: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS
2020 ($MILLION)
- FIGURE 14 U.S: ACUTE LYMPHOCYTIC PIPELINE REGIMENS/DRUGS MARKET SHARE, BY
TYPES, 2015 VS 2020
- FIGURE 15 CANADA: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS
2020
- FIGURE 16 CANADA: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS
2020
- FIGURE 17 U.K: EXISTING REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2010 VS 2020
- FIGURE 18 U.K: PIPELINE REGIMENS/DRUGS MARKET SHARE, BY TYPES, 2015 VS 2020
- FIGURE 19 GERMANY: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS
MARKET SHARE, BY TYPES, 2010 VS 2020
- FIGURE 20 GERMANY: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS
MARKET SHARE, BY TYPES, 2015 VS 2020
- FIGURE 21 FRANCE: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS
MARKET SHARE, BY TYPES, 2010 VS 2020
- FIGURE 22 FRANCE: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS
MARKET SHARE, BY TYPES, 2015 VS 2020
- FIGURE 23 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET
SHARE, BY TYPES, 2010 VS 2020
- FIGURE 24 ITALY: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET
SHARE, BY TYPES, 2015 VS 2020
- FIGURE 25 SPAIN ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET
SHARE, BY TYPES, 2010 VS 2020
- FIGURE 26 SPAIN: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET
SHARE, BY TYPES, 2015 - 2020
- FIGURE 27 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA EXISTING REGIMENS/DRUGS MARKET
SHARE, BY TYPES, 2010 VS 2020
- FIGURE 28 JAPAN: ACUTE LYMPHOCYTIC LEUKEMIA PIPELINE REGIMENS/DRUGS MARKET
SHARE, BY TYPES, 2015 VS 2020
- FIGURE 29 KEY GROWTH STRATEGIES (JANUARY 2008 - SEPTEMBER 2011)
|
